PREVENT Model Improves Hypertension Management Outcomes
- This article details new updates to hypertension guidelines,focusing on the integration of the PREVENT-CVD equation to personalize blood pressure (BP) treatment. HereS a breakdown of the key takeaways:
- * PREVENT-CVD Equation: This equation is now central to guiding BP treatment decisions, considering not just BP levels but also risk of heart failure (HF) and atherosclerotic...
- In essence,the new guidelines aim for a more personalized,risk-based approach to hypertension management,focusing on identifying the right patients for the right treatment at the right time.
Summary of the New Hypertension Guidelines & PREVENT-CVD Equation
This article details new updates to hypertension guidelines,focusing on the integration of the PREVENT-CVD equation to personalize blood pressure (BP) treatment. HereS a breakdown of the key takeaways:
* PREVENT-CVD Equation: This equation is now central to guiding BP treatment decisions, considering not just BP levels but also risk of heart failure (HF) and atherosclerotic cardiovascular disease (CVD). It’s a notable improvement over previous guidelines.
* treatment Thresholds: The updated guidelines recommend initiating antihypertensive medication for patients with:
* Systolic BP ≥ 140 mm hg
* Diastolic BP ≥ 90 mm hg
* PREVENT-CVD risk score ≥ 7.5%
* Systolic BP ≥ 130 mm Hg despite 3-6 months of lifestyle changes
* Diastolic BP ≥ 80 mm Hg despite 3-6 months of lifestyle changes
* Existing CVD, diabetes, or chronic kidney disease.
* Lifestyle Intervention First: For patients with stage 1 hypertension and a PREVENT-CVD risk below 7.5%, a trial of lifestyle interventions is recommended before medication. Medication is initiated if BP doesn’t improve.
* Risk Equivalence: The 7.5% PREVENT-CVD threshold is equivalent to a 10% risk using the pooled cohort Equation and a 15% risk using the Framingham Risk Score.
* Addressing Heart Failure: Including HF risk in the equation is crucial, as HF is a growing cause of mortality.
* implementation Challenges: Accomplished adoption relies on integrating the PREVENT-CVD equation into electronic health records (ehrs).
* Patient Communication: Future research will focus on how to best communicate risk estimates to patients, with “heart age” being a potentially more understandable metric. The researchers have developed an online tool to calculate PREVENT risk age: https://nwkhanlab.shinyapps.io/riskage/
* Social Determinants of Health: The article also acknowledges that CV risk factors and social determinants of health can accelerate “heart age.”
In essence,the new guidelines aim for a more personalized,risk-based approach to hypertension management,focusing on identifying the right patients for the right treatment at the right time.